This proposal describes the organization of a comprehensive, multidisciplinary international HIV Vaccine Trials Network (HVTN). Components of the HVTN include a Leadership Coordinating and Operations Center (L. Corey, Contact PI; S. Hammer and G. Gray, PI's); a Statistical and Data Management Center (P. Gilbert, PI) and a Network Laboratory Program (M. J. McElrath, PI). The HVTN's mission is to provide an objective and transparent platform to evaluate candidate HIV vaccines for the prevention of HIV infection in adult and adolescent populations globally. To achieve this, the HVTN will perform safety, immunogenicity, and efficacy trials of candidate HIV vaccines and adjuvants; conduct head-to-head comparisons of candidate vaccines; develop laboratory and statistical approaches to define potential correlates of protection; design trials to estimate the effects of vaccines tha reduce HIV acquisition and reduction in set point viremia transmission; conduct trials of candidate vaccines in special populations, such as adolescents and intravenous drug users; develop standardized risk reduction counseling methods; and collaborate with other NIH networks, federal agencies and non-governmental research organizations to advance the highest quality HIV vaccine research with optimal efficiency and cost effectiveness.
The progression of the HIV epidemic, as well as the international, political, and economic toll, make a compelling case for an effective HIV vaccine. While other prevention strategies offer important advances in slowing the rate of spread of HIV, the high incidence of asymptomatic persistently HIV-infected persons requires the development of an effective vaccine. In order to reduce the spread of this global pandemic, a robust integrated laboratory and clinical trials network is a necessary driver of the HIV vaccine field.
|Bekker, Linda-Gail; Gray, Glenda E (2017) Hope for HIV control in southern Africa: The continued quest for a vaccine. PLoS Med 14:e1002241|
|Li, Shuying S; Kochar, Nidhi K; Elizaga, Marnie et al. (2017) DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA. Clin Vaccine Immunol 24:|
|Richardson, Sharise; Seekaew, Pich; Koblin, Beryl et al. (2017) Barriers and facilitators of HIV vaccine and prevention study participation among Young Black MSM and transwomen in New York City. PLoS One 12:e0181702|
|Janes, Holly E; Cohen, Kristen W; Frahm, Nicole et al. (2017) Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial. J Infect Dis 215:1376-1385|
|Painter, Julia E; DiClemente, Ralph J; Jimenez, Lauren et al. (2017) Exploring evidence for behavioral risk compensation among participants in an HIV vaccine clinical trial. Vaccine 35:3558-3563|
|Andriesen, Jessica; Bull, Sheana; Dietrich, Janan et al. (2017) Using Digital Technologies in Clinical HIV Research: Real-World Applications and Considerations for Future Work. J Med Internet Res 19:e274|
|Cohen, Myron S; Corey, Lawrence (2017) Broadly neutralizing antibodies to prevent HIV-1. Science 358:46-47|
|Huang, Yunda; Zhang, Lily; Janes, Holly et al. (2017) Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials. Vaccine 35:1184-1193|
|Corey, Lawrence; Gray, Glenda E (2017) Preventing acquisition of HIV is the only path to an AIDS-free generation. Proc Natl Acad Sci U S A 114:3798-3800|
|Wang, Linbo; Richardson, Thomas S; Zhou, Xiao-Hua (2017) Causal analysis of ordinal treatments and binary outcomes under truncation by death. J R Stat Soc Series B Stat Methodol 79:719-735|
Showing the most recent 10 out of 161 publications